|Slideshows|October 12, 2017

How to Use Light Therapy in Bipolar Disorder

A novel protocol lights the way for a promising treatment for bipolar depression.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

ByJessica Walters

May 29th 2026

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

ByMark Zimmerman, MD

May 27th 2026

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

ByJessica Walters

May 20th 2026

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

ByLeah Kuntz

May 18th 2026

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

ByVeerle Bergink, MD

May 17th 2026

Latest CME

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Register now!

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

How to Use Light Therapy in Bipolar Disorder

Related Content

New Analysis of BXCL501 At-Home Administration Shows Reduction of Agitation in Bipolar and Schizophrenia

The Significant Presence of Comorbidities in Bipolar Depression: Insights From Mark Zimmerman, MD

Bipolar Disorder With Mixed Features: Recognition and Treatment, With Roger McIntyre, MD, at APA

New Data From IMPACT-TD Registry: Only 23% of Young Adults With Mood Disorders and Tardive Dyskinesia Symptoms Are Formally Diagnosed

Decision-Making and Risk Assessment in Perinatal Psychopharmacology

Latest CME

Southern California Psychiatry Conference

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

FDA Issues CRL for CTx-1301 for Treatment of ADHD

Endangered Education: Psychiatric Professional Degrees Under Attack

Adjunctive Atypical Antipsychotics in Major Depressive Disorder: Comparing Efficacy and Tolerability

New Name, New Path for Psychiatry: The Future of the DSM